Jeremie Capron, of research firm Robo Global, calls these companies the "enablers." They provide the tools and services to help a drug developer identify, test and ultimately manufacture a product.
Hosted on MSN
As the GLP-1 race heats up, how can investors position themselves for the next wave of innovation?
Investors Should Know: The GLP-1 and broader metabolic disease drug space is advancing rapidly, with next-generation oral formulations, triple-acting compounds, and combination therapies moving ...
Alex Carchidi calls the biotech sector highly risky and speculative, and says diversification is key for investors. Funding is currently difficult to obtain in the biotech industry, but a turnaround ...
Palatin Technologies Stock is quiet on the news front this Sunday, so the focus shifts to a background look at the biotech’s development path, pipeline orientation and where the shares stand in the ...
Biotechnology recruiting is hot. It''s more active than IT and telecommunications and it isn''t suffering the shortages in other areas of healthcare, says Frank Heasley, PhD, President and CEO, of ...
Amgen stock gets a Sunday background treatment, with a look at the biotech group’s history, key therapies and financial profile. The focus is on understanding the business rather than on a specific ...
Fintel reports that on August 11, 2023, HC Wainwright & Co. reiterated coverage of IO Biotech (NASDAQ:IOBT) with a Buy recommendation. As of August 2, 2023, the average one-year price target for IO ...
SA Spotlight uses AI to summarize content published on Seeking Alpha. All summaries are reviewed by human editors prior to publication. GLP-1 receptor agonists have reshaped the treatment landscape ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results